318 related articles for article (PubMed ID: 25605481)
1. Systematic review of surgery and outcomes in patients with primary aldosteronism.
Muth A; Ragnarsson O; Johannsson G; Wängberg B
Br J Surg; 2015 Mar; 102(4):307-17. PubMed ID: 25605481
[TBL] [Abstract][Full Text] [Related]
2. Systematic review of the clinical outcomes of mineralocorticoid receptor antagonist treatment versus adrenalectomy in patients with primary aldosteronism.
Satoh M; Maruhashi T; Yoshida Y; Shibata H
Hypertens Res; 2019 Jun; 42(6):817-824. PubMed ID: 30948836
[TBL] [Abstract][Full Text] [Related]
3. Adrenalectomy is comparable with medical treatment for reduction of left ventricular mass in primary aldosteronism: meta-analysis of long-term studies.
Marzano L; Colussi G; Sechi LA; Catena C
Am J Hypertens; 2015 Mar; 28(3):312-8. PubMed ID: 25336498
[TBL] [Abstract][Full Text] [Related]
4. SFE/SFHTA/AFCE consensus on primary aldosteronism, part 6: Adrenal surgery.
Steichen O; Amar L; Chaffanjon P; Kraimps JL; Ménégaux F; Zinzindohoue F
Ann Endocrinol (Paris); 2016 Jul; 77(3):220-5. PubMed ID: 27297451
[TBL] [Abstract][Full Text] [Related]
5. Renal Outcomes in Medically and Surgically Treated Primary Aldosteronism.
Hundemer GL; Curhan GC; Yozamp N; Wang M; Vaidya A
Hypertension; 2018 Sep; 72(3):658-666. PubMed ID: 29987110
[TBL] [Abstract][Full Text] [Related]
6. Outcomes analysis of surgical and medical treatments for patients with primary aldosteronism.
Park KS; Kim JH; Yang YS; Hong AR; Lee DH; Moon MK; Choi SH; Shin CS; Kim SW; Kim SY
Endocr J; 2017 Jun; 64(6):623-632. PubMed ID: 28458337
[TBL] [Abstract][Full Text] [Related]
7. Effect of Eplerenone on the Glomerular Filtration Rate (GFR) in Primary Aldosteronism: Sequential Changes in the GFR During Preoperative Eplerenone Treatment to Subsequent Adrenalectomy.
Nakano Y; Yoshimoto T; Fukuda T; Murakami M; Bouchi R; Minami I; Hashimoto K; Fujii Y; Kihara K; Ogawa Y
Intern Med; 2018 Sep; 57(17):2459-2466. PubMed ID: 29709927
[TBL] [Abstract][Full Text] [Related]
8. Treatment of primary aldosteronism: Where are we now?
Karagiannis A
Rev Endocr Metab Disord; 2011 Mar; 12(1):15-20. PubMed ID: 21305359
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic Outcomes with Surgical and Medical Management of Primary Aldosteronism.
Wachtel H; Fraker DL
Curr Cardiol Rep; 2021 Jun; 23(7):89. PubMed ID: 34081226
[TBL] [Abstract][Full Text] [Related]
10. Mineralocorticoid Receptor Antagonists and Clinical Outcomes in Primary Aldosteronism: As Good as Surgery?
Sechi LA; Colussi GL; Novello M; Uzzau A; Catena C
Horm Metab Res; 2015 Dec; 47(13):1000-6. PubMed ID: 26667803
[TBL] [Abstract][Full Text] [Related]
11. Long-term effect of specific treatment of primary aldosteronism on carotid intima-media thickness.
Holaj R; Rosa J; Zelinka T; Štrauch B; Petrák O; Indra T; Šomlóová Z; Michalský D; Novák K; Wichterle D; Widimský J
J Hypertens; 2015 Apr; 33(4):874-82; discussion 882. PubMed ID: 25490707
[TBL] [Abstract][Full Text] [Related]
12. Outcomes in unilateral primary aldosteronism after surgical or medical therapy.
Puar TH; Loh LM; Loh WJ; Lim DST; Zhang M; Tan PT; Lee L; Swee DS; Khoo J; Tay D; Tan SY; Zhu L; Gani L; King TF; Kek PC; Foo RS
Clin Endocrinol (Oxf); 2021 Feb; 94(2):158-167. PubMed ID: 33058182
[TBL] [Abstract][Full Text] [Related]
13. Progress in primary aldosteronism: mineralocorticoid receptor antagonists and management of primary aldosteronism in pregnancy.
Riester A; Reincke M
Eur J Endocrinol; 2015 Jan; 172(1):R23-30. PubMed ID: 25163723
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of drug-based and surgical treatments for primary aldosteronism.
Steichen O; Lorthioir A; Zinzindohoue F; Plouin PF; Amar L
Adv Chronic Kidney Dis; 2015 May; 22(3):196-203. PubMed ID: 25908468
[TBL] [Abstract][Full Text] [Related]
15. Composite Cardiovascular Outcomes in Patients With Primary Aldosteronism Undergoing Medical Versus Surgical Treatment: A Meta-Analysis.
Huang WC; Chen YY; Lin YH; Chueh JS
Front Endocrinol (Lausanne); 2021; 12():644260. PubMed ID: 34079522
[TBL] [Abstract][Full Text] [Related]
16. Mineralocorticoid receptor antagonists and renal involvement in primary aldosteronism: opening of a new era.
Catena C; Colussi G; Sechi LA
Eur J Endocrinol; 2013 Jan; 168(1):C1-5. PubMed ID: 23082005
[TBL] [Abstract][Full Text] [Related]
17. [Diagnosis and treatment outcome in primary aldosteronism based on a retrospective analysis of 187 cases].
Szücs N; Gláz E; Varga I; Tóth M; Kiss R; Patócs A; Jakab C; Perner F; Járay J; Horányi J; Dabasi G; Molnár F; Major L; Füto L; Rácz K; Tulassay Z
Orv Hetil; 2006 Jan; 147(2):51-9. PubMed ID: 16509213
[TBL] [Abstract][Full Text] [Related]
18. SFE/SFHTA/AFCE consensus on primary aldosteronism, part 7: Medical treatment of primary aldosteronism.
Pechère-Bertschi A; Herpin D; Lefebvre H
Ann Endocrinol (Paris); 2016 Jul; 77(3):226-34. PubMed ID: 27315759
[TBL] [Abstract][Full Text] [Related]
19. [Primary aldosteronism: analysis of a series of 54 patients].
Sabio JM; Mediavilla-García JD; Jaén F; Fernández-Torres C; Aliaga L; Jiménez-Alonso J
Med Clin (Barc); 2005 May; 124(20):765-8. PubMed ID: 15927101
[TBL] [Abstract][Full Text] [Related]
20. Medical or surgical therapy for primary aldosteronism: post-treatment follow-up as a surrogate measure of comparative outcomes.
Kline GA; Pasieka JL; Harvey A; So B; Dias VC
Ann Surg Oncol; 2013 Jul; 20(7):2274-8. PubMed ID: 23504117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
